Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. The company is headquartered in Bunkyo-Ku, Tokyo-To and currently employs 13,506 full-time employees. The firm operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Russia, Oceania), Asia and Latin America (Korea, Taiwan, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The firm is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.
How did ESAIY's recent EPS compare to expectations?
The most recent EPS for Eisai Co., Ltd. is $-11.53, not beating expectations of $16.99.
How did Eisai Co., Ltd. ESAIY's revenue perform in the last quarter?
Eisai Co., Ltd. revenue for the last quarter is $-11.53
What is the revenue estimate for Eisai Co., Ltd.?
According to 5 of Wall street analyst, the revenue estimate of Eisai Co., Ltd. range from $229.12B to $195.31B
What's the earning quality score for Eisai Co., Ltd.?
Eisai Co., Ltd. has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Eisai Co., Ltd. report earnings?
Eisai Co., Ltd. next earnings report is expected in 2026-08-13
What are Eisai Co., Ltd.'s expected earnings?
Eisai Co., Ltd. expected earnings is $196.55B, according to wall-street analysts.
Did Eisai Co., Ltd. beat earnings expectations?
Eisai Co., Ltd. recent earnings of $205.42B beat expectations.